The drugmaker expects the multi-channel initiative to lay its foundation in the ophthalmology market.
Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.
Agencies are testing out strategies to reach gender parity at a time when questions of discrimination are still front and center.
A massive disappointment for Bristol-Myers Squibb’s Opdivo in first-line lung cancer has leveled the playfield for Merck’s Keytruda.
Photo credit: Pictures of Money/Creative Commons
Will this payer pressure pose an existential threat to co-pay cards even though patients love them?